Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.87M
Average 0.88M
CLYM Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Climb Bio, Inc.NASDAQ: CLYM
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $5.84M rose 2.6% year over year, behind the +7.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +32.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.84M+5.6% QoQ
- Last fiscal yearDec 2025
- $21.17M+32.1% YoY
- LTMMar 2026
- $21.29M+7.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.6% | -100.0% | -102.6 pp |
| 1 year | +32.1% | -100.0% | -132.1 pp |
| 3-year CAGR | +3.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 21.17M USD
- Year-over-year change
- +32.1%
- 4-year CAGR
- +14.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.17M | +32.1% |
| FY2024 | 2024-12-31 | 16.03M | -35.5% |
| FY2023 | 2023-12-31 | 24.86M | +31.4% |
| FY2022 | 2022-12-31 | 18.92M | +53.2% |
| FY2021 | 2021-12-31 | 12.35M | — |
Selling, General & Admin vs competitors
How CLYM compares with its peers on the latest reported figures
- CLYM's LTM Mar 2026 selling, general & admin of $21.29M is the 4th highest of the 5 companies compared; the peer median is $28.05M.
- Its year-over-year change of +7.5% is the 3rd highest of 5, against a peer median of +15.8%.
- Over three fiscal years its annual growth of +3.8% compares with a peer median of +25.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| LTM Mar 2026 | $28.39M | -5.3% | +25.8% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $27.71M | +38.6% | +59.9% | 834.2% |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $21.29M | +7.5% | +3.8% | — |
| LTM Mar 2026 | $16.54M | -15.6% | +10.2% | — | |
| Peer median (excluding CLYM) | $28.05M | +15.8% | +25.8% | 834.2% | |
Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 97K |
| Gross Profit | 0 | 0 | 0 | 0 | (97K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.32M | 26.21M | 15.41M | 14.34M | 46.62M |
| Selling, General & Admin | 12.35M | 18.92M | 24.86M | 16.03M | 21.17M |
| Operating Expenses | 35.67M | 45.14M | 40.28M | 82.02M | 67.79M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| EBITDA | (47.48M) | (45.24M) | (35.12M) | (30.36M) | (59.75M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.67M) | (45.14M) | (40.28M) | (82.02M) | (67.88M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.38M | 4.62M | 8.13M | 8.32M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (11.81M) | (109K) | 5.16M | 8.12M | 8.03M |
| Income Before Tax | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| EPS (Diluted) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) |
| Weighted Avg Shares | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
| Weighted Avg Shares (Diluted) | 12.26M | 26.31M | 26.99M | 48.16M | 67.81M |
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.